To view or add a comment, sign in The FDA approved an expanded label for Merck's pulmonary arterial hypertension (PAH) drug Winrevair (sotatercept-csrk) that now includes components of clinical worsening events specifically hospitalisations for PAH, lung transplants and death based on results from the Phase III ZENITH study
it often signals that your current dose has reached its optimal effect, and further progress may require modest dose escalation
Post-approval, the FDA continues to monitor the safety of drugs like Wegovy and Ozempic
Combining them amplifies gastrointestinal disruption, increases constipation risk, and compounds the risk of fat-soluble vitamin malabsorption (vitamins A, D, E, K)
Combining objective circumference or scan data with subjective recovery and performance gives a richer view of change and whether Lcarnitine is offering practical benefit
During the evaluation, the nurse will gather subjective and objective data related to the patients physical, psychosocial, and diagnostic status
